American journal of nephrologySep 9, 2026

Orforglipron and Kidney Health: Potential Benefits or Risks? The Need for Studies on Kidney Outcomes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 10, 2026

Abstract

Orforglipron may offer an effective treatment option for patients with chronic kidney disease due to its unique pharmacokinetic profile.

Orforglipron has shown significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers.
Phase 3 trials indicated stable estimated glomerular filtration rate (eGFR) with no significant renal toxicity observed.
The trials did not specifically evaluate renal outcomes such as eGFR progression or albuminuria.
Previous studies often excluded or underrepresented patients with advanced chronic kidney disease.
Further clinical trials are needed to assess the safety and efficacy of orforglipron specifically in CKD populations.

Simplified

Orforglipron, the first oral non-peptide GLP-1 receptor agonist, has a pharmacokinetic and formulation profile that may be theoretically attractive for patients with chronic kidney disease (CKD) including hepatic metabolism with minimal renal excretion and removal of potential barriers associated with current injectable and other oral formulations. We utilized a literature search utilizing PubMed/MEDLINE and ClinicalTrials. gov from their respective inceptions through May 2026 to synthesize a review on orforglipron. Phase 3 trials demonstrated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers with stable eGFR and no indications of significant renal toxicity. These trials however were not designed or powered to evaluate renal outcomes including eGFR, albuminuria, and kidney failure progression. Additionally, previous trials were noted to have underrepresented or excluded populations of patients with advanced CKD, thus renal effects are inferential barring further clinical investigation, though a current trial examining kidney and cardiovascular outcomes in patients with both atherosclerosis and CKD is underway. Future CKD-specific trials are necessary to determine the safety, efficacy, and potential integration of orforglipron into nephrology treatment algorithms.

Orforglipron and Kidney Health: Potential Benefits or Risks? The Need for Studies on Kidney Outcomes

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief